107 related articles for article (PubMed ID: 4369891)
1. Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
Blackard CE; Byar DP; Seal US; Doe RP
N Engl J Med; 1974 Oct; 291(15):751-5. PubMed ID: 4369891
[No Abstract] [Full Text] [Related]
2. Serum corticosteroid-binding globulin, cortisol, and nonprotein-bound cortisol levels in patients receiving estrogen for carcinoma of the prostate.
Blackard CE; Doe RP; Seal US
Invest Urol; 1973 Nov; 11(3):194-7. PubMed ID: 4584161
[No Abstract] [Full Text] [Related]
3. Endocrine treatment of cancer of the prostate.
Madsen PO; Pedersen JF; Knuth OE
Wis Med J; 1970 Jul; 69(7):177-81. PubMed ID: 4916084
[No Abstract] [Full Text] [Related]
4. Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Seal US; Doe RP; Byar DP; Corle DK
Cancer; 1976 Sep; 38(3):1095-107. PubMed ID: 182347
[TBL] [Abstract][Full Text] [Related]
5. Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Seal US; Doe RP; Byar DP; Corle DK
Cancer; 1976 Sep; 38(3):1108-17. PubMed ID: 182348
[TBL] [Abstract][Full Text] [Related]
6. Correlation of pre-treatment serum 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
Blackard CE; Byar DP; Seal US; Doe RP
J Urol; 1975 Apr; 113(4):517-20. PubMed ID: 163929
[TBL] [Abstract][Full Text] [Related]
7. Cancer of the prostate.
N Engl J Med; 1968 Apr; 278(15):848-9. PubMed ID: 5642506
[No Abstract] [Full Text] [Related]
8. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group.
Surg Gynecol Obstet; 1967 May; 124(5):1011-7. PubMed ID: 6022476
[No Abstract] [Full Text] [Related]
9. Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Seal US; Doe RP; Byar DP; Corle DK
Cancer; 1978 Oct; 42(4):1720-9. PubMed ID: 213184
[No Abstract] [Full Text] [Related]
10. [Hormone therapy of cancer of the prostate gland].
Madsen PO; Pedersen IF; Knut OE
Urol Nefrol (Mosk); 1970; 35(3):25-8. PubMed ID: 4915239
[No Abstract] [Full Text] [Related]
11. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
[No Abstract] [Full Text] [Related]
12. Cancer of the prostate:estrogen therapy: natural conjugated estrogen vs. Stillbestrol: A point of view.
Kaplan L
Rev Surg; 1968; 25(5):323-9. PubMed ID: 4301296
[No Abstract] [Full Text] [Related]
13. Estrogen and survival data in carcinoma of the prostate.
Bennett AH; Dowd JB; Harrison JH
Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
[No Abstract] [Full Text] [Related]
14. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
15. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
[No Abstract] [Full Text] [Related]
16. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
17. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
18. [Hormone treatment in the prostatic cancer].
Madsen PO; Pedersen JF; Knuth OE
Urologe; 1969; 8(6):330-3. PubMed ID: 5405377
[No Abstract] [Full Text] [Related]
19. Elevated nonprotein-bound cortisol (NPC) in pregnancy, during estrogen administration and in carcinoma of the prostate.
Doe RP; Dickinson P; Zinneman HH; Seal US
J Clin Endocrinol Metab; 1969 Jun; 29(6):757-66. PubMed ID: 5783579
[No Abstract] [Full Text] [Related]
20. [Treatment of clinically localized prostatic cancer--endocrine therapy].
Hirano A
Hinyokika Kiyo; 1996 Oct; 42(10):829-32. PubMed ID: 8951483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
